Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops

Journal of Pathology

Volumn 184, Issue 1, 1998, Pages 44-52

  De Jong, Johannes S ^a   Van Diest, Paul J ^a   Van Der Valk, Paul ^a   Baak, Jan P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast carcinoma; Growth factor receptors; Growth factors; Immunohistochemistry

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH INHIBITOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; ENDOTHELIUM; EPITHELIUM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH INHIBITORS; GROWTH SUBSTANCES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; PARACRINE COMMUNICATION; RECEPTORS, GROWTH FACTOR; STROMAL CELLS;

EID: 0031910169     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199801)184:1<44::AID-PATH984>3.0.CO;2-H     Document Type: Article

References (52)

1. Aaltomaa S, Lipponen P, Eskelinen M, et al. Prognostic factors in axillary lymph node-negative (pN - ) breast carcinomas. Eur J Cancer 1991; 27: 1555-1559.
2. Baak JPA, Dop H van Kurver PHJ Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-382.
3. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68: 1309-1317.
4. Diest PH van, Baak JPA. The morphometric multivariate prognostic index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients.. Hum Pathol 1992; 22: 479-489.
5. Uyterlinde AM, Schipper NW, Baak JPA, Peterse H, Matze P. Limited prognostic value of cellular DNA content to classical and morphological parameters in invasive ductal breast cancer. Am J Clin Pathol 1988; 89: 301-307.
6. Craft PS, Harris LA. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994; 5: 305-311.
7. Folkman J, Klagsbrun M. Tumor angiogenesis. Effect on tumor growth and immunity. In: Gottlieb A, Plescia OJ, Bishop DHL, eds. Fundamental Aspects of Neoplasia. New York: Springer-Verlag, 1975.
8. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82: 4-6.
9. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 1991; 51: 4685-4692.
10. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273-280.
11. Peyrot JP, Bonneterne J, Hondermarck H, Hecquet B, Adenis A, Louchez MM. Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer. J Steroid Biochem Mol Biol 1992; 43: 87-94.
12. Anan K, Morisaki T, Katano M, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333-339.
13. Seymour L, Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Tr 1994; 32: 229-233.
14. Coltrera MP, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995; 55: 2703-2708.
15. Salomon DS, Zwiebel JA, Bano M. Presence of transforming growth factors in human breast cancer cells. Cancer Res 1984; 44: 4069-4077.
16. Macias A, Perez R, Hagenstrom T. Identification of transforming growth factor alpha in human primary breast carcinomas. Anticancer Res 1987; 7: 1271-1275.
17. Coombes RC, Barrett-Lee P, Luqmani Y. Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 1990; 37: 833-837.
18. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasari N. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I, and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990; 10: 1115-1126.
19. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol 1991; 138: 1527-1534.
20. Dublin EA, Barnes DM, Wang DY, King RJ, Levison DA. TGF alpha and TGF beta expression in mammary carcinoma. J Pathol 1993; 170: 15-22.
21. Castellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD. Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast carcinoma. An immunohistologic study. Cancer 1994; 73: 344-349.
22. Panico L, D'Antonio A, Salvatore G, et al. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996; 65: 51-56.
23. Brown LF, Berse B, Jackman RW. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
24. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumour angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85: 1045-1049.
25. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; i: 1398-1402.
26. Lewis S, Locker A, Todd JH. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990; 143: 385-389.
27. Gasparini G, Bevilacqua P, Pozza F, et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 1992; 66: 970-976.
28. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-428.
29. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993; 67: 1408-1412.
30. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, Miller WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 1994; 69: 1006-1009.
31. Auvinen P, Lipponen P, Johansson R, Syrjänen K. Prognostic significance of TGF-β1 and TGF-β2 expression in female breast cancer. Anticancer Res 1995; 15: 2627-2632.
32. Amoils KD, Seymour L, Bezwoda WR. Comparison between immunocytochemical and polymerase chain reaction techniques for detection of oestrogen receptor and transforming growth factor beta in breast cancer. Br J Cancer 1996; 74: 1255-1259.
33. Ethier SP. Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 1995; 87: 964-973.
34. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987.
35. Moscatelli D, Joseph-Silverstein J, Manejias R, Rifkin DB. Mr 25,000 heparin-binding protein from guinea pig brain is a high molecular weight form of basic fibroblast growth factor. Proc Natl Acad Sci USA 1987; 84: 5778-5782.
36. Sorvillo JM, McCormack ES, Yanez L, Valenzuela D, Reynolds FH Jr. Preparation and characterization of monoclonal antibodies specific for human transforming growth factor α. Oncogene 1990; 5: 377-386.
37. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 1994; 370: 341-347.
38. Qi CF, Liscia DS, Normanno N, et al. Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 1994; 69: 903-910.
39. Umekita Y, Enokizono N, Sagara Y. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-α) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. Virchows Arch A [Pathol Anat Histopathol] 1992; 420: 345-351.
40. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 1988; 48: 3898-3904.
41. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor β: biological function and chemical structure. Science 1986; 233: 532-534.
42. Walker RA, Gallacher B. Determination of transforming growth factor beta 1 mRNA expression in breast carcinomas by in situ hybridization. J Pathol 1995; 177: 123-127.
43. Starksen NF, Harsch GR, Gibbs VC, Williams LT. Regulated expression of the platelet-derived growth factor A chain in microvascular endothelial cells. J Biol Chem 1987; 262: 14381-14384.
44. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol 1995; 8: 665-670.
45. Schöllmann C, Grugel R, Tatje D, et al. Basic fibroblast growth factor modulates the mitogenic potency of the platelet-derived growth factor (PDGF) isoforms by specific up-regulation of the PDGF α receptor in vascular smooth muscle cells. J Biol Chem 1992; 267: 18032-18039.
46. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135-147.
47. Waltenberger J, Claesson-Welsh L, Sieghalin A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt 1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995.
48. Kalkoven E, Roelen BA, de Winter JP, et al. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumour cell lines. Cell Growth Differ 1995; 6: 1151-1161.
49. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 1991; 51: 4978-4985.
50. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jurtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-162.
51. Sainsbury JRC, Nicholson S, Angus B, Farndon JR, Malcolm AJ, Harris AL. Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer 1988; 58: 458-460.
52. de Jong JS, van Diest PJ, van der Valk P, Baak JPA. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.. J Pathol 1998; 184: 53-57.